GlaxoSmithKline Pharmaceuticals Ltd - Company Profile
Powered by 
All the data and insights you need on GlaxoSmithKline Pharmaceuticals Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date GlaxoSmithKline Pharmaceuticals Ltd Strategy Report
- Understand GlaxoSmithKline Pharmaceuticals Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
GlaxoSmithKline Pharmaceuticals Ltd (GSK India), a subsidiary of GlaxoSmithKline Plc, manufactures and markets prescription medicines and vaccines. The prescription medicines include analgesics, anti-infectives, cardiovascular, anti-inflammatory, diabetes, anti-parasitic, dermatology, endocrine, gastrointestinal and gynaecology products, immunosupressants, respiratory, nutritional, central nervous system (CNS) and oncology drugs. The company offers a range of vaccines for the prevention of hepatitis A, hepatitis B, influenzae, diphtheria, tetanus, pertussis, rotavirus, tetanus toxoid, human papillomavirus vaccine and others. The company has one subsidiary and one owned manufacturing unit. The company markets its products through distributors in the Middle East, Asia, Europe, Latin America, Africa, Australia, Singapore, and Russia among others. GSK India is headquartered in Mumbai, Maharashtra, India.
Headquarters
India
Address
Dr Annie Besant Road, Worli, Mumbai, Maharashtra, 400030
Website
india-pharma.gsk.com/en-in
Telephone
91 22 24959595
No of Employees
3,680
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GLAXO (NSE)
Revenue (2022)
$414.4M
-0.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-64%
(2022 vs 2021)
Market Cap*
$4.0B
Net Profit Margin (2022)
XYZ
-63.7%
(2022 vs 2021)
* As of and is in US$
GlaxoSmithKline Pharmaceuticals Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Prescription drugs |
| Vaccines |
| Specialty drugs |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In May, the company partnership with Amitabh Bachchan for shingles awareness and prevention. |
| 2023 | Contracts/Agreements | In May, the company entered a partnership with GSK to raise awareness about shingles. |
| 2023 | New Product Approvals | In May, the company launches Shingrix in India, a vaccine for the prevention of shingles in adults aged 50 years and above. |
Competitor Comparison
| Key Parameters | GlaxoSmithKline Pharmaceuticals Ltd | Astellas Pharma Inc | Aurobindo Pharma Ltd | Dr. Reddy's Laboratories Ltd | Aarti Drugs Ltd |
|---|---|---|---|---|---|
| Headquarters | India | Japan | India | India | India |
| City | Mumbai | Chuo-Ku | Hyderabad | Hyderabad | Mumbai |
| State/Province | Maharashtra | Tokyo | Telangana | Telangana | Maharashtra |
| No. of Employees | 3,680 | 14,484 | 15,690 | 24,832 | 1,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Juby Chandy | Chief Financial Officer; Director | Executive Board | - | - |
| Renu S. Karnad | Chairperson | Executive Board | 2019 | 66 |
| Upendra Singh | Head - General Medicines | Senior Management | - | - |
| Simrat Sohal | India Compliance Officer | Senior Management | - | - |
| Sunder Ramachandran | Head - Commercial Excellence | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward